Europe Pulmonary Arterial Hypertension Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Pulmonary Arterial Hypertension Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Pulmonary Arterial Hypertension Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Pulmonary Arterial Hypertension Market Regional Analysis

6.2 Europe Pulmonary Arterial Hypertension Market Revenue 2020-2028 (US$ Million)

6.3 Europe Pulmonary Arterial Hypertension Market Forecast Analysis

7. Europe Pulmonary Arterial Hypertension Market Analysis – by Drugs

7.1 Endothelin Receptor Antagonists

7.1.1 Overview
7.1.2 Endothelin Receptor Antagonists: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

7.2 Prostacyclin and Prostacyclin Analogs

7.2.1 Overview
7.2.2 Prostacyclin and Prostacyclin Analogs: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

7.3 sGC Stimulators

7.3.1 Overview
7.3.2 sGC Stimulators: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

7.4 pde-5 Dipsticks

7.4.1 Overview
7.4.2 pde-5 Dipsticks: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

8. Europe Pulmonary Arterial Hypertension Market Analysis – by Type

8.1 Branded and Generics

8.1.1 Overview
8.1.2 Branded and Generics: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

9. Europe Pulmonary Arterial Hypertension Market Analysis – by Route of Administration

9.1 Oral

9.1.1 Overview
9.1.2 Oral: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

9.2 Intravenous/Subcutaneous

9.2.1 Overview
9.2.2 Intravenous/Subcutaneous: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

9.3 Inhalational

9.3.1 Overview
9.3.2 Inhalational: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

10. Europe Pulmonary Arterial Hypertension Market Analysis – by Distribution Channel

10.1 Hospital Pharmacies and Clinics

10.1.1 Overview
10.1.2 Hospital Pharmacies and Clinics: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

10.2 Online Pharmacies

10.2.1 Overview
10.2.2 Online Pharmacies: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

10.3 Retail Pharmacies

10.3.1 Overview
10.3.2 Retail Pharmacies : Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)

11. Europe Pulmonary Arterial Hypertension Market – Europe Analysis

11.1 Overview

11.2 Europe

11.2.1 Europe Pulmonary Arterial Hypertension Market Breakdown, by Key Country, 2023 and 2028 (%)
11.2.1.1 Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast Analysis – by Country
11.2.1.1 UK: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.1.1 UK: Europe Pulmonary Arterial Hypertension Market Breakdown, by Drugs
11.2.1.1.2 UK: Europe Pulmonary Arterial Hypertension Market Breakdown, by Type
11.2.1.1.3 UK: Europe Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
11.2.1.1.4 UK: Europe Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel

11.2.1.2 Germany: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.2.1 Germany: Europe Pulmonary Arterial Hypertension Market Breakdown, by Drugs
11.2.1.2.2 Germany: Europe Pulmonary Arterial Hypertension Market Breakdown, by Type
11.2.1.2.3 Germany: Europe Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
11.2.1.2.4 Germany: Europe Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel

11.2.1.3 France: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.3.1 France: Europe Pulmonary Arterial Hypertension Market Breakdown, by Drugs
11.2.1.3.2 France: Europe Pulmonary Arterial Hypertension Market Breakdown, by Type
11.2.1.3.3 France: Europe Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
11.2.1.3.4 France: Europe Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel

11.2.1.4 Russia: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.4.1 Russia: Europe Pulmonary Arterial Hypertension Market Breakdown, by Drugs
11.2.1.4.2 Russia: Europe Pulmonary Arterial Hypertension Market Breakdown, by Type
11.2.1.4.3 Russia: Europe Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
11.2.1.4.4 Russia: Europe Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel

11.2.1.5 Italy: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.5.1 Italy: Europe Pulmonary Arterial Hypertension Market Breakdown, by Drugs
11.2.1.5.2 Italy: Europe Pulmonary Arterial Hypertension Market Breakdown, by Type
11.2.1.5.3 Italy: Europe Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
11.2.1.5.4 Italy: Europe Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel

11.2.1.6 Rest of Europe: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.6.1 Rest of Europe: Europe Pulmonary Arterial Hypertension Market Breakdown, by Drugs
11.2.1.6.2 Rest of Europe: Europe Pulmonary Arterial Hypertension Market Breakdown, by Type
11.2.1.6.3 Rest of Europe: Europe Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
11.2.1.6.4 Rest of Europe: Europe Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 Bayer AG

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 Gilead Sciences Inc

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 GSK Plc

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Johnson & Johnson

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Lupin Ltd

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Novartis AG

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 Pfizer Inc

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 Teva Pharmaceutical Industries Ltd

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 United Therapeutics Corp

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

Europe Pulmonary Arterial Hypertension Market